SCHEDULE: Liminatus Pharma Schedule 13D Filing

Valetudo Therapeutics LLC and Chris Kim jointly file Schedule 13D, reporting beneficial ownership of 14.3% of Liminatus Pharma's common stock.

Summary

• Valetudo Therapeutics LLC and Chris Kim have jointly filed a Schedule 13D, indicating their beneficial ownership of 9,617,954 shares of Liminatus Pharma, Inc. common stock.
• This represents 14.3% of the total outstanding common stock as of July 2, 2026.
• The filing details the acquisition of 3,448,926 shares and 48,975.10742 shares of Series A Non-Voting Convertible Preferred Stock in connection with Liminatus Pharma's acquisition of InnocsAI LLC.
• Chris Kim, as CEO and controlling member of Valetudo, has voting and dispositive power over these shares.
• The Reporting Persons acquired these shares for investment purposes and may review their investment strategy, potentially engaging in communications with management, shareholders, or third parties, and may buy or sell additional shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting beneficial ownership and investment intentions rather than new financial performance or strategic shifts.

Positives

• Joint filing indicates a coordinated approach to beneficial ownership reporting.
• Reporting Persons have acquired a significant stake (14.3%) in Liminatus Pharma, suggesting confidence in the company's potential.
• The acquisition of InnocsAI LLC, which led to the share acquisition, could be a strategic move for Liminatus Pharma.

Negatives

• The filing does not disclose the specific cost or source of funds for the shares acquired, beyond the Series A Preferred Stock consideration.
• The potential for future stock sales by the Reporting Persons could create downward pressure on the stock price.

Risks

• The Series A Preferred Stock conversion is contingent upon prior stockholder approval, which may not be obtained.
• Future actions by the Reporting Persons, such as selling shares or influencing corporate activities, could negatively impact the company or other shareholders.
• Potential for future communications with management and shareholders could lead to activist investor scenarios.

Future Outlook

The Reporting Persons intend to review their investment in Liminatus Pharma on a continuing basis and may take various actions, including acquiring additional securities, selling existing holdings, or engaging with management and shareholders regarding corporate activities, capitalization, and performance.

Management Comments

• Chris Kim is the Chief Executive Officer and controlling member of Valetudo Therapeutics LLC and has voting and dispositive power over the shares held by Valetudo.
• Mr. Kim disclaims any beneficial ownership except to the extent of his pecuniary interest.

Industry Context

StockSavvy.ai notes that this Schedule 13D filing by Valetudo Therapeutics LLC and Chris Kim signals a significant investment in Liminatus Pharma, Inc. The acquisition of InnocsAI LLC and the subsequent share allocation are key events in the pharmaceutical sector, often driven by M&A activity to enhance product pipelines or market access.

Related Party Transactions

• Valetudo Therapeutics LLC transferred 4,373,603 shares of common stock to Ewon Comfortech Co., Ltd on June 24, 2026, retaining voting power via a voting agreement.
• Valetudo received 3,448,926 shares of common stock and 48,975.10742 shares of Series A Non-Voting Convertible Preferred Stock from Liminatus Pharma in connection with the acquisition of InnocsAI LLC.

Stakeholder Impact

• Shareholders may be impacted by the potential for future stock sales by the Reporting Persons.
• Other shareholders may be affected by the Reporting Persons' potential influence over corporate activities.
• Management and the Board of Directors may engage in discussions with the Reporting Persons regarding company strategy and performance.

Next Steps

• Reporting Persons will continue to review their investment in Liminatus Pharma.
• Potential for future communications with Liminatus Pharma's management and Board of Directors.
• Potential for engaging with other shareholders or third parties regarding the investment.
• Possibility of purchasing additional shares or selling existing shares.

Key Dates

Recommendation

The filing primarily concerns beneficial ownership and investment intentions, with no new financial results or significant strategic announcements that would warrant a buy or sell recommendation. The potential for future actions by the reporting persons suggests a 'hold' stance pending further developments.

Keywords

Schedule 13D, Liminatus Pharma, Valetudo Therapeutics LLC, Chris Kim, Beneficial Ownership, Common Stock, Series A Preferred Stock, InnocsAI LLC